Valeant Pharma: A Debt Swap?

The debt-ridden drug maker's share price spiked more than 7% today due to speculation that a debt-to-equity swap could be on the horizon. This analysts explains why the notion holds such appeal.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.